Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819097) titled 'A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Pfizer
Condition:
Adult
Healthy Participants
Intervention:
Biological: RSVpreF
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 9, 2026
Target Sample Size: 600
Countries of Recruitment:
United States
China
United States
To know more, visit h...